{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-008805","form_type":"8-K","ticker":"OMER","cik":"0001285819","company_name":"OMEROS CORP","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.266075+00:00","generated_at":"2026-06-15T08:23:42.043566+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Omeros Q1 net loss $33.7M; receives $200M milestone; OMS906 data positive in PNH","bullets":["Net loss $33.7M ($0.54 per share) vs $33.0M ($0.53) Q1 2022; cash burn $23.6M excl $200M milestone.","Received $200M milestone from Rayner; OMIDRIA royalties $9.2M on $30.7M sales (down from $13.8M on $27.7M).","Plans BLA resubmission for narsoplimab in TA-TMA; meeting with FDA this month.","OMS906 in PNH: mean Hgb increased 3.4 g/dL at day 29; 100% of patients Hgb >=15.7 g/dL at day 113.","Awarded $6.69M NIDA grant for OMS527 in cocaine use disorder."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-008805","json":"https://secwatch.observer/filing/0001558370-23-008805.json","markdown":"https://secwatch.observer/filing/0001558370-23-008805.md","text":"https://secwatch.observer/filing/0001558370-23-008805.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1285819/000155837023008805/0001558370-23-008805-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1285819/000155837023008805/omer-20230509x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T08:23:42.043566+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bfce03d44979026647c79399dc8d03319cf24cf4","claim":"OMEROS CORP reported the first quarter ended March 31, 2023 results: net income Net loss was $33.7 million in the first quarter of 2023, or $0.54 per share, EPS $0.54 per share.","evidence_excerpt":"Net loss was $33.7 million in the first quarter of 2023, or $0.54 per share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1285819/000155837023008805/0001558370-23-008805-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Net income","value":"Net loss was $33.7 million in the first quarter of 2023, or $0.54 per share"},{"label":"EPS","value":"$0.54 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}